| Autor: |
Alexander Thomas, MD, Dean J. Kereiakes, MD, Andreas Baumbach, MD, Stephan Windecker, MD, Cody Pietras, BA, Ovidiu Dressler, MD, M. Ozgu Issever, MS, Michael Curtis, MD, Barry Bertolet, MD, James P. Zidar, MD, Pieter C. Smits, MD, Victor Alfonso Jiménez Díaz, MD, Brent McLaurin, MD, Ángel Cequier, MD, Akihiko Takahashi, MD, PhD, Louis A. Cannon, MD, Giovanni Amoroso, MD, PhD, Tsunekazu Kakuta, MD, PhD, Shigeru Saito, MD, Martin B. Leon, MD, Alexandra J. Lansky, MD |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of the Society for Cardiovascular Angiography & Interventions, Vol 1, Iss 2, Pp 100033- (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2772-9303 |
| DOI: |
10.1016/j.jscai.2022.100033 |
| Popis: |
Background: Patients with diabetes mellitus (DM) have worse outcomes following percutaneous coronary intervention than nondiabetic patients. The novel Supreme DES is a biodegradable polymer sirolimus-eluting stent designed to synchronize early drug delivery, limiting the potential for long-term inflammatory response. The purpose of this study was to evaluate the safety and efficacy of the Supreme DES in patients with DM. Methods: This is a prespecified analysis of the diabetic subgroup from the PIONEER III randomized (2:1), controlled trial, comparing the Supreme DES with a durable polymer everolimus-eluting stent (DP-EES). The primary safety and efficacy composite endpoint was target lesion failure at 1 year, a composite of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Results: The PIONEER III trial randomized 1629 patients, of which 494 (30.3%) had DM with 331 (398 lesions) randomly assigned to Supreme DES and 163 (208 lesions) to DP-EES. Among patients with DM, target lesion failure at 1 year was 6.1% (20/331) with Supreme DES vs 3.7% (6/163) with DP-EES (hazard ratio = 1.65; 95% confidence interval = 0.66-4.10, P = .28). The composite of cardiac death or target vessel myocardial infarction was 3.3% (11/331) with Supreme DES and 3.7% (6/163) with DP-EES (hazard ratio = 0.90; 95% confidence interval = 0.33-2.44, P = .83). There were no significant differences in other secondary endpoints. Conclusions: This prespecified substudy of the PIONEER III trial demonstrated the relative safety and efficacy of the novel Supreme DES when compared with commercially available DP-EES in diabetics at 1 year. Longer term follow-up will be required to ensure continued safety and efficacy of the Supreme DES. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
